Table 1
Clinical characteristics of 51 patients with PTCL
| Characteristics | Number of cases | Percentage(%) |
|---|---|---|
| Gender | ||
| Male | 32 | 62.7 |
| Female | 19 | 37.3 |
| Age(y) | 47.8 ± 19.1 (range, 9–83) | |
| Histology | ||
| PTCL-NOS | 27 | 52.9 |
| ALCL ALK+ | 8 | 13.7 |
| ALCL ALK- | 7 | 15.7 |
| AITL | 9 | 17.6 |
| Ann Arbor stage | ||
| I-II | 21 | 41.2 |
| III- IV | 30 | 58.8 |
| Clinical outcome | ||
| Progression or relapse within 24 months | 27 | 52.9 |
| No evidence of relapse within 24 months | 24 | 47.1 |
[i] ALCL ALK+ = anaplastic large cell lymphoma anaplastic lymphoma kinase positive; ALCL ALK- = ALCL anaplastic lymphoma kinase negative; AITL = angioimmunoblastic T-cell lymphoma; PTCL-NOS = PTCL-not otherwise specified
Table 2
CT findings of 51 patients with PTCL
| Characteristics | Number of cases | Percentage(%) |
|---|---|---|
| Involvement site | ||
| Single | 27 | 52.9 |
| Multiple | 24 | 47.1 |
| Tumor size(cm) | 6.0 ± 2.4 (range, 1.5–14.0) | |
| Tumor margin | ||
| Well-defined | 29 | 56.9 |
| Ill-defined with peritumoral invasion | 22 | 43.1 |
| Tumor shape | ||
| Round/oval | 17 | 33.3 |
| Irregular | 34 | 66.7 |
| Tumor density | ||
| Homogenous | 28 | 54.9 |
| Heterogeneous | 23 | 45.1 |
| Intratumoral necrosis | ||
| Present | 14 | 27.5 |
| Absent | 37 | 72.5 |
| Enhancement degree | ||
| Mild | 21 | 41.2 |
| Moderate | 30 | 58.8 |
| Lymph node involvement | ||
| Present | 32 | 62.7 |
| Absent | 19 | 37.3 |
Figure 1
A 13-year-old boy with PTCL in the anterior mediastinum. (A) Axial non-contrast CT image shows an oval, well-defined mass with homogeneous density in the anterior mediastinum (white arrow). (B) Contrast-enhanced CT image shows the tumor with homogeneously mild enhancement (white arrow). Tumor recurrence was not noted during the 36-month follow-up period.
Figure 2
A 54-year-old man with PTCL in the sinonasal cavity. (A) Axial non-contrast CT image shows an ill-defined, irregular mass with inhomogeneous density in the right nasal cavity, maxillary and sphenoid sinus (black arrows). (B) Contrast-enhanced CT image shows the tumor with heterogeneously moderate enhancement. Intratumoral necrosis is seen in the mass (black arrow). (C) Bony destruction is detected on non-contrast CT image. The tumor relapsed 11 months after therapy.
Figure 3
A 47-year-old man with PTCL in the anterior mediastinum. (A) Axial non-contrast CT image shows an ill-defined, irregular mass with inhomogeneous density in the anterior mediastinum (black arrow). Multiple pleural metastases are detected (white arrows). (B) Contrast-enhanced CT image shows the tumor with heterogeneously mild enhancement. Intratumoral necrosis is seen in the mass (black arrow). Lymphadenopathy is seen in the left axillary fossa (white arrows). (C, D, E) The left internal jugular vein is invaded by the tumor and vessel occlusion is detected on contrast-enhanced CT image and MPR images (white arrows). Tumor progression was found during therapy. This patient deceased at 3 months after therapy.
Figure 4
A 61-year-old man with PTCL in the deudenum. (A) Axial non-contrast CT image shows the thickening of the duodenal wall (white arrows).The lesion grows in an expansive centripetal fashion (black arrow) with an ill-defined margin and invasion of adjacent fatty tissue (thin black arrow). (B) Contrast-enhanced CT image shows the tumor with heterogeneously mild enhancement. Superior mesenteric artery and vein are encased by the tumor (white arrows). Tumor progression was found during therapy. This patient deceased at 5 months after therapy.
Table 3
Univariate analyses of CT findings
| Factor | Category | Number of good vs poor outcomes | P value |
|---|---|---|---|
| Involvement site | 0.016* | ||
| Single | 17:10 | ||
| Multiple | 7:17 | ||
| Tumor size | 0.328 | ||
| < 6.0cm | 14:13 | ||
| ≥ 6.0cm | 10:14 | ||
| Ill-defined margin with peritumoral invasion | < 0.001* | ||
| Present | 4:18 | ||
| Absent | 20:9 | ||
| Tumor shape | 0.617 | ||
| Round/oval | 8:9 | ||
| Irregular | 16:18 | ||
| Inhomogenous density | 0.001* | ||
| Present | 5:18 | ||
| Absent | 19:9 | ||
| Intratumoral necrosis | 0.025* | ||
| Present | 3:11 | ||
| Absent | 21:16 | ||
| Enhancement degree | 0.586 | ||
| Mild | 10:11 | ||
| Moderate | 14:16 | ||
| Lymph node involvement | 0.069 | ||
| Present | 12:20 | ||
| Absent | 12:7 |
[i] *P < 0.05